Final Multivariable Models Showing the Association of Independent Variables on Mortality and on Incident Comorbidity, Among Human Immunodeficiency Virus–Positive Participants Only
| Dependent Variable . | Outcome Mortality HR (95% CI) . | P Value . | Outcome Incident Comorbidity OR (95% CI) . | P Value . |
|---|---|---|---|---|
| Frailty phenotype | ||||
| Robust | Ref | ref | ||
| Prefrail | 1.96 (.71–5.39) | .192 | 1.08 (.74–1.57) | .678 |
| Frail | 3.19 (1.02–9.98) | .047 | 1.90 (1.06–3.41) | .032 |
| Age (per 10 y) | 1.94 (1.23–3.07) | .005 | 1.53 (1.20–1.96) | .001 |
| Sexual risk group | ||||
| MSM | … | ref | ||
| Heterosexual male | … | .90 (.50–1.63) | .731 | |
| Female | … | 1.84 (1.08–3.12) | .024 | |
| Nonwhite ethnicity | … | 1.18 (.62–2.22) | .617 | |
| Higher vocational education | … | .91 (.63–1.31) | .608 | |
| Smoking status | ||||
| Never | Ref | ref | ||
| Former | 1.16 (.35–3.87) | .804 | 1.04 (.67–1.62) | .847 |
| Current | 3.41 (1.19 –9.77) | .022 | 1.46 (.93–2.27) | .099 |
| Alcohol use | ||||
| Never | Ref | ref | ||
| Former | .27 (.06–1.16) | .078 | .74 (.34–1.61) | .451 |
| Current | .20 (.05–.77) | .019 | .69 (.35–1.35) | .274 |
| No. of preexisting comorbidities | ||||
| 0 | … | ref | ||
| 1 | … | .85 (.57–1.28) | .439 | |
| 2 | … | .87 (.51–1.47) | .596 | |
| ≥ 3 | … | .66 (.34–1.27) | .212 | |
| CD4 nadir (per 100 cells/μL higher) | 1.51 (1.06–2.14) | .022 | … | |
| Duration of zalcitabine use (y) | … | 1.35 (1.09–1.67) | .005 | |
| Cumulative duration of viral load > 1000 copies/mL | … | 1.06 (1.00–1.12) | .046 |
| Dependent Variable . | Outcome Mortality HR (95% CI) . | P Value . | Outcome Incident Comorbidity OR (95% CI) . | P Value . |
|---|---|---|---|---|
| Frailty phenotype | ||||
| Robust | Ref | ref | ||
| Prefrail | 1.96 (.71–5.39) | .192 | 1.08 (.74–1.57) | .678 |
| Frail | 3.19 (1.02–9.98) | .047 | 1.90 (1.06–3.41) | .032 |
| Age (per 10 y) | 1.94 (1.23–3.07) | .005 | 1.53 (1.20–1.96) | .001 |
| Sexual risk group | ||||
| MSM | … | ref | ||
| Heterosexual male | … | .90 (.50–1.63) | .731 | |
| Female | … | 1.84 (1.08–3.12) | .024 | |
| Nonwhite ethnicity | … | 1.18 (.62–2.22) | .617 | |
| Higher vocational education | … | .91 (.63–1.31) | .608 | |
| Smoking status | ||||
| Never | Ref | ref | ||
| Former | 1.16 (.35–3.87) | .804 | 1.04 (.67–1.62) | .847 |
| Current | 3.41 (1.19 –9.77) | .022 | 1.46 (.93–2.27) | .099 |
| Alcohol use | ||||
| Never | Ref | ref | ||
| Former | .27 (.06–1.16) | .078 | .74 (.34–1.61) | .451 |
| Current | .20 (.05–.77) | .019 | .69 (.35–1.35) | .274 |
| No. of preexisting comorbidities | ||||
| 0 | … | ref | ||
| 1 | … | .85 (.57–1.28) | .439 | |
| 2 | … | .87 (.51–1.47) | .596 | |
| ≥ 3 | … | .66 (.34–1.27) | .212 | |
| CD4 nadir (per 100 cells/μL higher) | 1.51 (1.06–2.14) | .022 | … | |
| Duration of zalcitabine use (y) | … | 1.35 (1.09–1.67) | .005 | |
| Cumulative duration of viral load > 1000 copies/mL | … | 1.06 (1.00–1.12) | .046 |
For further details, see Supplementary Table 3, model 5 and Supplementary Table 4, model 6.
Abbreviations: CI, confidence interval; HR, hazard ratio; MSM, men who have sex with men; OR, odds ratio.
Final Multivariable Models Showing the Association of Independent Variables on Mortality and on Incident Comorbidity, Among Human Immunodeficiency Virus–Positive Participants Only
| Dependent Variable . | Outcome Mortality HR (95% CI) . | P Value . | Outcome Incident Comorbidity OR (95% CI) . | P Value . |
|---|---|---|---|---|
| Frailty phenotype | ||||
| Robust | Ref | ref | ||
| Prefrail | 1.96 (.71–5.39) | .192 | 1.08 (.74–1.57) | .678 |
| Frail | 3.19 (1.02–9.98) | .047 | 1.90 (1.06–3.41) | .032 |
| Age (per 10 y) | 1.94 (1.23–3.07) | .005 | 1.53 (1.20–1.96) | .001 |
| Sexual risk group | ||||
| MSM | … | ref | ||
| Heterosexual male | … | .90 (.50–1.63) | .731 | |
| Female | … | 1.84 (1.08–3.12) | .024 | |
| Nonwhite ethnicity | … | 1.18 (.62–2.22) | .617 | |
| Higher vocational education | … | .91 (.63–1.31) | .608 | |
| Smoking status | ||||
| Never | Ref | ref | ||
| Former | 1.16 (.35–3.87) | .804 | 1.04 (.67–1.62) | .847 |
| Current | 3.41 (1.19 –9.77) | .022 | 1.46 (.93–2.27) | .099 |
| Alcohol use | ||||
| Never | Ref | ref | ||
| Former | .27 (.06–1.16) | .078 | .74 (.34–1.61) | .451 |
| Current | .20 (.05–.77) | .019 | .69 (.35–1.35) | .274 |
| No. of preexisting comorbidities | ||||
| 0 | … | ref | ||
| 1 | … | .85 (.57–1.28) | .439 | |
| 2 | … | .87 (.51–1.47) | .596 | |
| ≥ 3 | … | .66 (.34–1.27) | .212 | |
| CD4 nadir (per 100 cells/μL higher) | 1.51 (1.06–2.14) | .022 | … | |
| Duration of zalcitabine use (y) | … | 1.35 (1.09–1.67) | .005 | |
| Cumulative duration of viral load > 1000 copies/mL | … | 1.06 (1.00–1.12) | .046 |
| Dependent Variable . | Outcome Mortality HR (95% CI) . | P Value . | Outcome Incident Comorbidity OR (95% CI) . | P Value . |
|---|---|---|---|---|
| Frailty phenotype | ||||
| Robust | Ref | ref | ||
| Prefrail | 1.96 (.71–5.39) | .192 | 1.08 (.74–1.57) | .678 |
| Frail | 3.19 (1.02–9.98) | .047 | 1.90 (1.06–3.41) | .032 |
| Age (per 10 y) | 1.94 (1.23–3.07) | .005 | 1.53 (1.20–1.96) | .001 |
| Sexual risk group | ||||
| MSM | … | ref | ||
| Heterosexual male | … | .90 (.50–1.63) | .731 | |
| Female | … | 1.84 (1.08–3.12) | .024 | |
| Nonwhite ethnicity | … | 1.18 (.62–2.22) | .617 | |
| Higher vocational education | … | .91 (.63–1.31) | .608 | |
| Smoking status | ||||
| Never | Ref | ref | ||
| Former | 1.16 (.35–3.87) | .804 | 1.04 (.67–1.62) | .847 |
| Current | 3.41 (1.19 –9.77) | .022 | 1.46 (.93–2.27) | .099 |
| Alcohol use | ||||
| Never | Ref | ref | ||
| Former | .27 (.06–1.16) | .078 | .74 (.34–1.61) | .451 |
| Current | .20 (.05–.77) | .019 | .69 (.35–1.35) | .274 |
| No. of preexisting comorbidities | ||||
| 0 | … | ref | ||
| 1 | … | .85 (.57–1.28) | .439 | |
| 2 | … | .87 (.51–1.47) | .596 | |
| ≥ 3 | … | .66 (.34–1.27) | .212 | |
| CD4 nadir (per 100 cells/μL higher) | 1.51 (1.06–2.14) | .022 | … | |
| Duration of zalcitabine use (y) | … | 1.35 (1.09–1.67) | .005 | |
| Cumulative duration of viral load > 1000 copies/mL | … | 1.06 (1.00–1.12) | .046 |
For further details, see Supplementary Table 3, model 5 and Supplementary Table 4, model 6.
Abbreviations: CI, confidence interval; HR, hazard ratio; MSM, men who have sex with men; OR, odds ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
